Tipranavir

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tipranavir
Tipranavir.svg
Tipranavir 3D.png
Systematic (IUPAC) name
N-{3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3,4-dihydro-2H-pyran-5-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulfonamide
Clinical data
Trade names Aptivus
AHFS/Drugs.com monograph
MedlinePlus a606009
Licence data EMA:Link, US FDA:link
Pregnancy cat.
Legal status
Routes Oral
Pharmacokinetic data
Protein binding 99.9%
Metabolism Hepatic
Half-life 5–6 hours
Excretion Fecal
Identifiers
CAS number 174484-41-4 YesY
ATC code J05AE09
PubChem CID 65027
DrugBank DB00932
ChemSpider 10482313 YesY
UNII ZZT404XD09 YesY
ChEMBL CHEMBL183041 N
NIAID ChemDB 032941
PDB ligand ID TPV (PDBe, RCSB PDB)
Chemical data
Formula C31H33F3N2O5S 
Mol. mass 602.66 g/mol
 N (what is this?)  (verify)

Tipranavir, or tipranavir disodium, is a nonpeptidic protease inhibitor (PI) manufactured by Boehringer-Ingelheim under the trade name Aptivus. It is administered with ritonavir in combination therapy to treat HIV infection.

Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors and it recommended for patients who are resistant to other treatments. Resistance to tipranavir itself seems to require multiple mutations.[1]

Tipranavir was approved by the Food and Drug Administration (FDA) on June 22, 2005, and was approved for pediatric use on June 24, 2008.[2] Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with some drug resistance. However, side effects of tipranavir may be more severe than those of other anti-retrovirals. Some side effects include intracranial hemorrhage, hepatitis, hyperglycemia and diabetes mellitus. The drug has also been shown to cause increases in total cholesterol and triglycerides.[3]

References[edit]

  1. ^ Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley M (2005). "Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.". Antiviral Res 68 (1): 27–35. doi:10.1016/j.antiviral.2005.07.003. PMID 16122817. 
  2. ^ "New Aptivus (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients" (Press release). Boehringer Ingelheim. 2008-06-24. Retrieved 2008-09-02. 
  3. ^ "Aptivus® (tipranavir) capsules 250 mg, oral solution 100 mg/mL, Prescribing Information", Boehringer Inhelheim, 2012. Revised April 2012. [1]